WO2020230802A1 - 4-オキソピロリジン-3-カルボン酸アミド誘導体の製造方法 - Google Patents

4-オキソピロリジン-3-カルボン酸アミド誘導体の製造方法 Download PDF

Info

Publication number
WO2020230802A1
WO2020230802A1 PCT/JP2020/019047 JP2020019047W WO2020230802A1 WO 2020230802 A1 WO2020230802 A1 WO 2020230802A1 JP 2020019047 W JP2020019047 W JP 2020019047W WO 2020230802 A1 WO2020230802 A1 WO 2020230802A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
formula
alkali metal
production method
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/019047
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
啓太 三好
貴博 神田
秀孝 小松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Priority to CN202080029336.4A priority Critical patent/CN113727968B/zh
Priority to JP2021519448A priority patent/JPWO2020230802A1/ja
Publication of WO2020230802A1 publication Critical patent/WO2020230802A1/ja
Anticipated expiration legal-status Critical
Priority to JP2025084812A priority patent/JP2025114857A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a method for producing a pyrrolidine derivative, which can be used as an intermediate for producing an antibacterial agent effective against resistant bacteria.
  • Patent Document 1 describes 4-, which is an intermediate for producing an optically active substance of (3R, 4S) -3-alkylaminomethyl-4-fluoropyrrolidin, which is useful as a drug manufacturing intermediate, or an enantiomer thereof.
  • a method for producing an oxopyrrolidine-3-carboxylic acid amide derivative is disclosed.
  • Patent Document 1 The manufacturing method disclosed in Patent Document 1 has a large number of processes and has problems in industrial production. Therefore, an object of the present invention is to provide a novel method for producing a pyrrolidine derivative having a smaller number of steps.
  • the present inventors have diligently studied the above-mentioned problems and found that a pyrrolidine derivative can be efficiently synthesized by continuously performing the Azamichael reaction and Dieckmann cyclization, and arrived at the present invention.
  • Equation (1) [In formula (1), PG 1 represents a protecting group for an amino group, R 1 is a hydrogen atom, an alkyl group of C1 to C6 which may be substituted, or a cycloalkyl group of C3 to C8 which may be substituted. Represents. ] Is a method for producing a 4-oxopyrrolidine-3-carboxylic acid amide derivative. Process A: Equation (2) [In the formula (2), PG 1 represents the above-mentioned one, and R 2 represents an alkyl group of C1 to C6. ] And formula (3) [In equation (3), R 1 represents the above-mentioned one.
  • R 1 represents a hydrogen atom, an optionally substituted alkyl group of C1 to C6 or an optionally substituted cycloalkyl group of C3 to C8.
  • R 1 represents a hydrogen atom, an optionally substituted alkyl group of C1 to C6 or an optionally substituted cycloalkyl group of C3 to C8.
  • the production method according to [1], wherein the compound represented by the formula (2) obtained in the step C and the compound represented by the formula (3) obtained in the step B are subjected to the step A.
  • step A The production method according to [1] or [2], wherein in step A, the base is a hydride of an alkali metal.
  • step A The production method according to [1] or [2], wherein the base is an alkali metal amide in step A.
  • step A the solvent is cyclic ethers.
  • step A the reaction temperature is 40 to 50 ° C.
  • Amino-protecting group represented by PG 1 is aralkoxycarbonyl group, a functional group represented by R 1 is a cyclopropyl group, A process according to any one of [1] to [7].
  • step A the base is potassium tert-butoxide, sodium tert-pentoxide or potassium tert-pentoxide, and the solvent is cyclic ethers.
  • step A any of [1] to [3], wherein the base is potassium tert-butoxide, sodium tert-pentoxide or potassium tert-pentoxide, the solvent is cyclic ethers, and the reaction temperature is 40 to 50 ° C.
  • the base is potassium tert-butoxide, sodium tert-pentoxide or potassium tert-pentoxide
  • the solvent is cyclic ethers
  • the reaction temperature is 40-50 ° C
  • the protection of the amino group represented by PG 1 is protected.
  • group is aralkoxycarbonyl group
  • a functional group represented by R 1 is a cyclopropyl group, a process according to any one of [1] to [3].
  • the pyrrolidine derivative represented by the formula (1) can be obtained in a shorter process.
  • PG 1 represents a protecting group for an amino group.
  • R 1 represents a hydrogen atom, an alkyl group of C1 to C6 which may be substituted, or a cycloalkyl group of C3 to C8 which may be substituted.
  • R 2 represents an alkyl group of C1 to C6, and is preferably an alkyl group of C1 to C4.
  • X represents a leaving group and is preferably a halogen atom.
  • Cn to Cm shown in the present specification means n to m carbon atoms, and n and m are independent natural numbers, and m is a larger number than n.
  • C1 to C6 means 1 to 6 carbon atoms.
  • protecting group for an amino group shown in the present specification is not particularly limited as long as it is a protecting group generally known as a protecting group for an amino group, and is, for example, an aralkyl such as a benzyl group and a paramethoxybenzyl group.
  • an aralkylcarbonyl group or an alkoxycarbonyl group is preferable as a protecting group for the amino group, an aralkoxycarbonyl group is more preferable, and a benzyloxycarbonyl group is further preferable.
  • the “optionally substituted alkyl groups C1 to C6” referred to herein are halogen atoms, hydroxyl groups, cyano groups, C1 to C6 alkoxy groups, optionally substituted aryloxy groups, C1.
  • Good C4-C9 cyclic amino groups formylamino groups, C1-C6 alkylcarbonylamino groups, C1-C6 alkoxycarbonylamino groups, C1-C6 alkylsulfonylamino groups and optionally substituted arylsulfonylamino groups It means an alkyl group of C1 to C6 having the same or different 1 to 5 substituents selected from the group consisting of, or an unsubstituted alkyl group of C1 to C6.
  • alkyl group of C1 to C6 means a linear or branched alkyl group.
  • alkyl group of C1 to C6 include methyl group, ethyl group, propyl group, 1-methylethyl group, 1-methylpropyl group, 2-methylpropan-1-yl group, tert-butyl group and 1-ethyl.
  • Propyl group, 2-ethylpropyl group, butyl group, hexyl group and the like can be mentioned.
  • an ethyl group or a tert-butyl group is preferable as the alkyl group of C1 to C6.
  • the "optionally substituted cycloalkyl group of C3 to C8" referred to herein is a halogen atom, a hydroxyl group, a cyano group, an alkoxy group of C1 to C6, or an optionally substituted aryloxy group. , C1-C6 alkylcarbonyl groups, C1-C6 alkoxycarbonyl groups, C1-C6 alkylthio groups, amino groups, mono- or di-substituted C1-C6 alkylamino groups, including 1-3 heteroatoms.
  • Cyclic amino groups of C4 to C9, formylamino groups, alkylcarbonylamino groups of C1 to C6, alkoxycarbonylamino groups of C1 to C6, alkylsulfonylamino groups of C1 to C6 and optionally substituted arylsulfonyl It means a C3 to C8 cycloalkyl group having the same or different 1 to 5 substituents selected from the group consisting of amino groups, or an unsubstituted C3 to C8 cycloalkyl group.
  • cycloalkyl group of C3 to C8 means an alkyl group having a cycloalkyl ring.
  • examples of the cycloalkyl group of C3 to C8 include a cyclopropyl group, a cyclopropylmethyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group and a cyclooctyl group.
  • the cycloalkyl group of C3 to C8 is preferably a cyclopropyl group.
  • alkoxy group of C1 to C6 examples include a methoxy group, an ethoxy group, a butoxy group and a hexyloxy group.
  • aryloxy group consists of a halogen atom, a hydroxyl group, a cyano group, a nitro group, an alkyl group of C1 to C6, an alkoxy group of C1 to C6 and an alkylthio group of C1 to C6. It means an aryloxy group having the same or different 1 to 5 substituents selected from the group, or an unsubstituted aryloxy group.
  • aryloxy group examples include a phenoxy group and a naphthyloxy group.
  • alkylcarbonyl group of C1 to C6 examples include an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group and a hexanoyl group.
  • alkoxycarbonyl group of C1 to C6 examples include a methoxycarbonyl group, an ethoxycarbonyl group, and a tert-butoxycarbonyl group.
  • alkylthio groups of C1 to C6 include methylthio group, ethylthio group, propylthio group and isopropylthio group.
  • the above-mentioned "mono or di-substituted alkylamino group of C1 to C6” refers to a halogen atom, a hydroxyl group, a cyano group, an alkoxy group of C1 to C6, an alkylthio group of C1 to C6, an amino group, and 1 to 3 groups. From C4-C9 cyclic amino groups, formylamino groups, C1-C6 alkylcarbonylamino groups, C1-C6 alkylsulfonylamino groups and optionally substituted arylsulfonylamino groups, which may contain heteroatoms, and the like. It means an alkylamino group of C1 to C6 having 1 to 2 substituents selected from the group.
  • alkylamino group of C1 to C6 examples include methylamino group, ethylamino group, n-propylamino group, n-butylamino group, sec-butylamino group, n-pentylamino group and n-.
  • a hexylamino group and the like can be mentioned.
  • cyclic amino group of C4 to C9 which may contain 1 to 3 heteroatoms
  • the cyclic amino group of C4 to C9 include an aziridyl group, a pyrrolidyl group, a piperidyl group, a morpholic group, an oxazolyl group, an azabicycloheptyl group and an azabicyclooctyl group.
  • alkylcarbonylamino group of C1 to C6 examples include an acetylamino group, a propionylamino group and a butyrylamino group.
  • alkoxycarbonylamino group of C1 to C6 examples include a methoxycarbonylamino group, an ethoxycarbonylamino group, a tert-butoxycarbonylamino group, a hexyloxycarbonylamino group and the like.
  • alkylsulfonylamino group of C1 to C6 examples include a methylsulfonylamino group and an ethylsulfonylamino group.
  • arylsulfonylamino group is derived from a halogen atom, a hydroxyl group, a cyano group, a nitro group, an alkyl group of C1 to C6, an alkoxy group of C1 to C6 and an alkylthio group of C1 to C6. It means an arylsulfonylamino group having the same or different 1 to 5 substituents selected from the group, or an unsubstituted arylsulfonylamino group.
  • arylsulfonylamino group examples include a phenylsulfonylamino group, a 4-methylphenylsulfonylamino group and a naphthylsulfonylamino group.
  • alkyl group of C1 to C4" shown in the present specification means a linear or branched alkyl group.
  • Examples of the "alkyl groups C1 to C4" include methyl group, ethyl group, propyl group, 1-methylethyl group, 1-methylpropyl group, 2-methylpropan-1-yl group, tert-butyl group and butyl. Group etc. can be mentioned. Among these, a methyl group or an ethyl group is preferable as the alkyl group of C1 to C4, and an ethyl group is more preferable.
  • alkali metal examples include lithium, sodium and potassium.
  • Examples of the “leaving group” shown in the present specification include a halogen atom, a p-toluenesulfonyloxy group, and a methanesulfonyloxy group.
  • a halogen atom is preferable as a leaving group.
  • halogen atom examples include an iodine atom, a bromine atom, a chlorine atom, and a fluorine atom. Among these, a chlorine atom is preferable as the halogen atom.
  • cyclic ethers examples include 1,4-dioxane, tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), tetrahydropyran and the like. Among these, tetrahydrofuran is preferable as the cyclic ethers.
  • the reaction of step C is a step of introducing a protecting group into the compound represented by the formula (4) to obtain the compound represented by the formula (2).
  • a protecting group for example, Theodra W. et al. Green & Peter G. M. The methods described in Wuts, "Greene's Protective Groups in Organic Synthesis", future edition, Wiley-Interscience, 2006 can be mentioned.
  • benzyl chloroformate a base, and a solvent can be used for production.
  • the amount of benzyl chloroformate is not particularly limited with respect to the compound represented by the formula (4), but is usually preferably 1 to 5 equivalents, more preferably 1 to 2 equivalents, and most preferably 1.05 equivalents. ..
  • the base may be any base that does not inhibit the reaction, and examples thereof include sodium hydrogencarbonate. Usually, 1 to 5 equivalents are preferable, more preferably 2 to 3 equivalents, and most preferably 2.2 equivalents. is there.
  • the solvent examples include esters such as ethyl acetate, butyl acetate and isopropyl acetate, 1,4-dioxane, tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), tert-butylmethyl ether (TBME) and dimethoxy.
  • esters such as ethyl acetate, butyl acetate and isopropyl acetate
  • 1,4-dioxane tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), tert-butylmethyl ether (TBME) and dimethoxy.
  • Examples include ethers such as ethane (DME) and jiglime, water, and mixtures thereof.
  • the reaction temperature is usually preferably in the range of ⁇ 20 ° C. to the boiling point of the solvent to be used, more preferably in the range of 0 ° C
  • Step B is a step of condensing the compound represented by the formula (5) and the amine compound represented by the formula (6) in the presence of a base to obtain the compound represented by the formula (3).
  • condensation reaction commonly used condensation conditions can be used.
  • the amount of the amine represented by the formula (6) is not particularly limited, but is usually preferably 1 to 3 equivalents, more preferably 1.0 to 1.5 equivalents, relative to the compound represented by the formula (5). Is.
  • the base may be any base that does not inhibit the reaction, such as triethylamine, trimethylamine, tripropylamine, diisopropylethylamine, pyridine, dimethylaniline, N-methylmorpholine, N-methylpyrrolidin, and 4-dimethylaminopyridine.
  • Organic bases can be mentioned.
  • N-methylmorpholine, N-methylpyrrolidine or triethylamine is preferable, and triethylamine is more preferable.
  • a solvent for the reaction in step B It is usually preferable to use a solvent for the reaction in step B.
  • the solvent include esters such as ethyl acetate and butyl acetate, aromatic compounds such as benzene, toluene and xylene, hydrocarbons such as hexane, heptane and cyclohexane, 1,4-dioxane and tetrahydrofuran (THF).
  • Cyclic ethers such as 2-methyltetratetra (2-MeTHF), tetrahydropyran, ethers such as tert-butylmethyl ether (TBME), dimethoxyethane (DME) and diglime, dichloromethane, chloroform, carbon tetrachloride and 1,2 Examples thereof include halogenated hydrocarbons such as dichloroethane, nitriles such as acetonitrile, amides such as N, N-dimethylformamide (DMF), N, N-dimethylacetamide and N-methylpyrrolidone, and mixtures thereof.
  • 2-MeTHF 2-methyltetratetra
  • ethers such as tert-butylmethyl ether (TBME), dimethoxyethane (DME) and diglime
  • dichloromethane chloroform
  • carbon tetrachloride 1,2 Examples thereof include halogenated hydrocarbons such as dichloroethane
  • esters such as ethyl acetate and butyl acetate, mixed solvents of tetrahydrofuran, tetrahydrofuran and N, N-dimethylformamide, or 2-methyltetrahydrofuran and N, N-dimethyl are preferable solvents to be used in step B.
  • a mixed solvent with formamide is preferable, and ethyl acetate is more preferable.
  • the reaction temperature in step B is usually preferably in the range of ⁇ 20 ° C. to the boiling point of the solvent to be used, more preferably in the range of 0 ° C. to the boiling point of the solvent, and further preferably in the range of 0 to 10 ° C.
  • step A is carried out by treating the compound represented by the formula (2) and the compound represented by the formula (3) with at least one base selected from an alkali metal amide, an alkali metal hydride and an alkali metal alkoxide. , A step of obtaining a 4-oxopyrrolidine-3-carboxylic acid amide derivative represented by the formula (1).
  • Alkaline metal amide is a compound in which hydrogen atoms of amines are replaced with metal atoms.
  • alkali metal amide examples include lithium amide, sodium amide, potassium amide, lithium diethylamide, lithium diisopropylamide, lithium cyclohexylisopropylamide, lithium tetramethylpiperidide, lithium hexamethyldisilazide (LHMDS), and sodium hexamethyldi.
  • LHMDS lithium hexamethyldisilazide
  • KHMDS potassium hexamethyldisilazide
  • lithium hexamethyldisilazide sodium hexamethyldisilazide or potassium hexamethyldisilazide is preferable, and potassium hexamethyldisilazide is more preferable.
  • alkali metal alkoxide is a compound in which the hydroxyl groups of alcohols are replaced with alkali metals.
  • alkali metal alkoxide examples include sodium methoxide (NaOMe), sodium ethoxide (NaOEt), potassium ethoxide (KOEt), sodium tert-butoxide (tBuONa), potassium tert-butoxide (tBuOK), and lithium tert-butoxide (tBuOK).
  • tBuOLi sodium tert-pentoxide (C 2 H 5 C (CH 3 ) 2 ONa) and potassium tert-pentoxide (C 2 H 5 C (CH 3 ) 2 OK) and the like.
  • alkali metal alkoxide potassium tert-butoxide, sodium tert-pentoxide or potassium tert-pentoxide is preferable, and potassium tert-butoxide is more preferable.
  • alkali metal hydride examples include lithium hydride, sodium hydride, potassium hydride and the like.
  • the amount of the base used is not particularly limited, but is usually preferably 1 to 4 equivalents, more preferably 1 to 1.5 equivalents, relative to the compound represented by the formula (2).
  • the reaction temperature in step A is usually preferably in the range of ⁇ 20 to 100 ° C., more preferably 30 to 65 ° C., and even more preferably 40 to 50 ° C.
  • a solvent for the reaction in step A It is usually preferable to use a solvent for the reaction in step A.
  • the solvent include alcohols such as methanol, ethanol, 2-propanol, tert-butyl alcohol, 2-methoxyethanol, ethylene glycol and diethylene glycol, esters such as ethyl acetate and butyl acetate, and benzene, toluene and xylene.
  • Aromatic compounds such as hexane, heptane and cyclohexane, cyclic ethers such as 1,4-dioxane, tetrahydrofuran and 2-methyltetrahexyl, ethers such as tert-butylmethyl ether, dimethoxyethane and diglime, dichloromethane , Hydrocarbons such as chloroform, carbon tetrachloride and 1,2-dichloroethane, nitriles such as acetonitrile, amides such as N, N-dimethylformamide (DMF), N, N-dimethylacetamide and N-methylpyrrolidone. Classes, and mixtures thereof.
  • hydrocarbons such as hexane, heptane and cyclohexane
  • cyclic ethers such as 1,4-dioxane, tetrahydrofuran and 2-methyltetrahexyl
  • ethers such
  • N N-dimethylformamide, tetrahydrofuran or toluene is preferable, and tetrahydrofuran is more preferable.
  • the pyrrolidine derivative can be obtained in a shorter process.
  • the method of this embodiment has a better yield than the method described in Patent Document 1, does not require the use of expensive reagents, and has less by-products in the reaction. Therefore, the method of this embodiment is more suitable for industrial production of the pyrrolidine derivative represented by the formula (1).
  • the 4-oxopyrrolidine-3-carboxylic acid amide derivative obtained by the method of the present embodiment is useful as a pharmaceutical manufacturing intermediate by known methods (Patent No. 5844739 and WO 2007/102567). It can be converted to an optically active form of 3R, 4S) -3-alkylaminomethyl-4-fluoropyrrolidine or an enantiomer thereof.
  • double amount means the amount (mL) of solvent relative to the mass (g) of the substrate.
  • reaction solution was cooled to room temperature and the organic layer was separated.
  • a 10% sodium chloride solution 200 mL was added to the organic layer, the organic layer was separated, and then concentrated under reduced pressure.
  • Ethyl acetate 150 mL was added to the concentrated residue to dissolve it, and the mixture was concentrated under reduced pressure to obtain 91.5 g of the title compound as a colorless oil.
  • Step B Production of N-Cyclopropylacrylamide Cyclopropylamine (39.9 mL, 473 mmol) and triethylamine (71.9 mL, 516 mmol) were added to ethyl acetate (300 mL). After cooling, a solution of acryloyl chloride (34.7 mL, 430 mmol) / ethyl acetate (75.0 mL) was added dropwise at an internal temperature of 10 ° C. or lower, and the mixture was stirred at an internal temperature of 10 ° C. or lower for 1 hour.
  • Step A Preparation of benzyl 3- (Cyclopropyl Carbamoyl) -4-oxopyrrolidine-1-carboxylate N-Carbobenzoxiglysin methyl (91.5 g) synthesized in tetrahydrofuran (200 mL) by step C and N- synthesized by step B. Cyclopropylacrylamide (52.6 g) was added. After heating, a tetrahydrofuran solution of potassium tert-butoxide (1.0 mol / L, 394 mL, 394 mmol) was added dropwise at an internal temperature of 45 ° C. to 50 ° C., and the mixture was stirred at an internal temperature of 45 ° C. to 50 ° C. for 2.5 hours.
  • potassium tert-butoxide 1.0 mol / L, 394 mL, 394 mmol
  • the mixture was stirred at an internal temperature of 0 ° C. to 10 ° C. for 30 minutes, and the remaining 1 mol / L hydrochloric acid and water (250 mL) were added dropwise at an internal temperature of 0 ° C. to 10 ° C. After heating and stirring at an internal temperature of 30 ° C. to 35 ° C. for 30 minutes, the mixture was cooled and stirred at an internal temperature of 0 ° C. to 10 ° C. for 30 minutes. The precipitated crystals were collected by filtration and washed with water (500 mL) to obtain 165 g of wet crystals of the title compound.
  • Example 2 Preparation of benzyl 3- (Cyclopropylcarbamoyl) -4-oxopyrrolidine-1-carboxylate N-carbobenzoxicglycine methyl (93.9 g) synthesized in tetrahydrofuran (300 mL) according to Step C of Example 1 and Example 1 N-cyclopropylacrylamide (52.5 g) synthesized in step B of the above step B was added. After heating, a tetrahydrofuran solution (21%, 211 g) of potassium tert-butoxide was added dropwise at an internal temperature of 45 ° C. to 50 ° C., and the mixture was stirred at an internal temperature of 45 ° C. to 50 ° C. for 2.5 hours.
  • the mixture was stirred at an internal temperature of 0 ° C. to 10 ° C. for 30 minutes, and the remaining 1 mol / L hydrochloric acid and water (250 mL) were added dropwise at an internal temperature of 0 ° C. to 10 ° C. After heating and stirring at an internal temperature of 30 ° C. to 35 ° C. for 30 minutes, the mixture was cooled and stirred at an internal temperature of 0 ° C. to 10 ° C. for 30 minutes. The precipitated crystals were collected by filtration and washed with water (500 mL) to obtain 154 g of wet crystals of the title compound.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/JP2020/019047 2019-05-14 2020-05-13 4-オキソピロリジン-3-カルボン酸アミド誘導体の製造方法 Ceased WO2020230802A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202080029336.4A CN113727968B (zh) 2019-05-14 2020-05-13 4-氧代吡咯烷-3-甲酰胺衍生物的制备方法
JP2021519448A JPWO2020230802A1 (cg-RX-API-DMAC7.html) 2019-05-14 2020-05-13
JP2025084812A JP2025114857A (ja) 2019-05-14 2025-05-21 4-オキソピロリジン-3-カルボン酸アミド誘導体の製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-091100 2019-05-14
JP2019091100 2019-05-14

Publications (1)

Publication Number Publication Date
WO2020230802A1 true WO2020230802A1 (ja) 2020-11-19

Family

ID=73288868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/019047 Ceased WO2020230802A1 (ja) 2019-05-14 2020-05-13 4-オキソピロリジン-3-カルボン酸アミド誘導体の製造方法

Country Status (3)

Country Link
JP (2) JPWO2020230802A1 (cg-RX-API-DMAC7.html)
CN (1) CN113727968B (cg-RX-API-DMAC7.html)
WO (1) WO2020230802A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060194A (en) * 1960-03-29 1962-10-23 American Cyanamid Co 4-cyano-3-oxo-pyrrolidine carboxylates
JP2006503106A (ja) * 2002-09-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 統合失調症を処置するためのヘテロ環式置換ピペラジン
WO2012057093A1 (ja) * 2010-10-25 2012-05-03 杏林製薬株式会社 3,4-二置換ピロリジン誘導体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1701072A (zh) * 2002-09-17 2005-11-23 沃纳-兰伯特公司 用于治疗精神分裂症的杂环取代的哌嗪
WO2017119503A1 (ja) * 2016-01-08 2017-07-13 株式会社ジーンデザイン ゾル-ゲル法で作製される無機多孔質体を用いた核酸合成用担体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060194A (en) * 1960-03-29 1962-10-23 American Cyanamid Co 4-cyano-3-oxo-pyrrolidine carboxylates
JP2006503106A (ja) * 2002-09-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 統合失調症を処置するためのヘテロ環式置換ピペラジン
WO2012057093A1 (ja) * 2010-10-25 2012-05-03 杏林製薬株式会社 3,4-二置換ピロリジン誘導体の製造方法

Also Published As

Publication number Publication date
CN113727968B (zh) 2024-08-23
CN113727968A (zh) 2021-11-30
JPWO2020230802A1 (cg-RX-API-DMAC7.html) 2020-11-19
JP2025114857A (ja) 2025-08-05

Similar Documents

Publication Publication Date Title
KR102630456B1 (ko) 브리바라세탐의 제조 방법
JP5548129B2 (ja) 不斉有機触媒
KR100980379B1 (ko) 광학활성을 갖는 5-히드록시-3-옥소헵타노에이트 유도체의제조방법
US7429613B2 (en) Process for the preparation of atorvastatin and intermediates
CN113727968B (zh) 4-氧代吡咯烷-3-甲酰胺衍生物的制备方法
JP4783998B2 (ja) (3r,5s)−7−置換−3,5−ジヒドロキシヘプト−6−エン酸の製法
EP2560952B1 (en) Production of atorvastatin low in lactone impurities
JP5932641B2 (ja) 3−置換−4−フルオロピロリジン誘導体の製造方法
CN101045695B (zh) 用于制备喹诺酮中间体的氢化还原方法
JP5844739B2 (ja) 3,4−二置換ピロリジン誘導体の製造方法
US7842818B2 (en) Process for preparation of tetrasubstituted 5-azaspiro[2.4]- heptane derivatives and optically active intermediates thereof
EP1693364B1 (en) Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates
CA2786646A1 (en) Method for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof
JP2012532145A (ja) トランス−4−アミノシクロペンタ−2−エン−1−カルボン酸誘導体の製造
JP4181233B2 (ja) ピロリジン−2,4−ジオン誘導体の製法
NO20024046L (no) Fremgangsmåte for fremstilling av kinolonkarboksylsyrer og mellomprodukter derav
KR100896087B1 (ko) 광학적으로 순수한 2-메틸피롤리딘 및 그 염의 제조방법
KR100424393B1 (ko) 옥시라세탐의 제조방법
JP2000026408A (ja) 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
JP2001288167A (ja) ピロール−2−カルボン酸誘導体の製造法
JP2005120067A (ja) 光学活性シクロプロピルアミン誘導体およびその製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20805065

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021519448

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20805065

Country of ref document: EP

Kind code of ref document: A1